3 juni 2018: lees ook dit artikel: 


29 november 2011: ik ben kanker-actueel aan het herzien en kwam onderstaand artikel tegen over PDT met het niet toxische talaporfin sodadium als photosenthesizeer. De meest recente studie uit april 2011 staat onderaan dit artikel met als conclusie: a clinically effective dose of talaporfin sodium was well-tolerated and that cutaneous photosensitivity was mild and resolved relatively rapidly oftewel talaporfin is een veilig middel bij PDT.

17 oktober 2006: Bron: Gan To Kagaku Ryoho. 2004 Jun;31(6):979-85 en Anticancer Res. 2003 Nov-Dec;23(6C):4897-900

Een nieuwe photosenthesizer, talaporfin sodium, voor gebruik bij PDT - Photodynamishe Therapie is door de FDA goedgekeurd voor gebruik bij verschillende vormen van kanker. De auteurs melden dat zij vooral succes hebben bij longkankertumoren (85,7% volledige vernietiging van de tumoren). Onder eerste abstract een abstract van een studie met muizen met inwendige tumoren, welke studie volgens de auteurs ook succesvol verliep met dezelfde photosenshesizer.

[Development of a novel photosensitizer, talaporfin sodium, for the photodynamic therapy (PDT)][Article in Japanese]
Tsukagoshi S; Tokyo Cooperative Oncology Group.

Recently, in Japan, a novel photosensitizer, talaporfin sodium was developed for the photodynamic therapies of various diseases including malignant tumors. At the same time, a diode laser device, Panalas 6405, to be used for this therapy was developed. Talaporfin was first extracted and refined from plant chlorophyll and was found that the skin photosensitivity caused by drug disappeared faster than the existing photosensitizer. Clinically, in the patients with early lung cancer, the complete response was obtained in 85.7% of the lesions (36/42 lesions) by the administration of 40 mg/m2 followed by laser irradiation at 100 J/cm2 4-6 hours later. The sensitivity disappeared mostly within 2 weeks.

PMID: 15222124 [PubMed - indexed for MEDLINE]

1: Anticancer Res. 2003 Nov-Dec;23(6C):4897-900.

Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.Kikuchi T, Asakura T, Aihara H, Shiraki M, Takagi S, Kinouchi Y, Aizawa K, Shimosegawa T. Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai 980-8574, Japan. dr_tatsu@pg.highway.ne.jp

BACKGROUND: To clarify the usefulness of the second-generation photosensitizer, mono-L-aspartyl chlorin e6 (NPe6), we examined the possibility of photodynamic diagnosis and photodynamic therapy for intestinal tumors in a mouse model.

MATERIALS AND METHODS: NPe6 was intravenously administered to the tumor-bearing mice through the tail vein. The intestinal tumor sites were irradiated with a 664-nm diode laser at constant intervals after the administration of photosensitizers. The tumors were excised and fluorescence was observed in frozen sections by microscope.

RESULTS: We observed the fluorescent image and calculated that the mean fluorescence intensity was significantly higher in the tumors than the normal mucosa during 6 hours (p < 0.05). The fluorescence of NPe6 was chiefly accumulated in the intestinal tumors as red fluorescence on the fluorescent microphotographic image.

CONCLUSION: We conclude that NPe6 may be a valuable photosensitizer for the photodynamic diagnosis and photodynamic therapy of intestinal tumors.

PMID: 14981942 [PubMed - indexed for MEDLINE]

Characterization of cutaneous photosensitivity in healthy volunteers receiving talaporfin sodium

Bron: Photodermatol Photoimmunol Photomed. 2011 Apr;27(2):85-9. doi: 10.1111/j.1600-0781.2011.00573.x

Characterization of cutaneous photosensitivity in healthy volunteers receiving talaporfin sodium

  1. Elizabeth Bromley,
  2. Brittany Briggs,
  3. Llew Keltner,
  4. Sy-Shi Wang

Article first published online: 10 MAR 2011

DOI: 10.1111/j.1600-0781.2011.00573.x

Photodermatology, Photoimmunology & Photomedicine

Photodermatology, Photoimmunology & Photomedicine

Volume 27, Issue 2, pages 85–89, April 2011

Purpose: Historically, cutaneous photosensitivity has been the most common side effect of treatment with light-activated drugs. Talaporfin sodium is a water soluble photosensitizer in commercial use and clinical development that is cleared from the body relatively rapidly. This trial was conducted to determine the period of skin photosensitivity in healthy subjects given talaporfin sodium and to determine the correlation between photosensitivity and plasma levels of talaporfin sodium.

Methods: Twenty healthy volunteers were dosed with 0.25–1.0 mg/kg talaporfin sodium and exposed at successive timepoints to a solar simulator applied to a small patch of skin on the back. Photosensitivity was assessed at these sites 24 h later. Duration of photosensitivity and correlation with plasma drug concentration were analyzed.

Results: Skin reactions were generally mild and were classified most commonly as asymptomatic erythema. Photosensitivity subsided in each subject between 1 and 3 weeks after dosing. Subjects no longer exhibited photosensitivity at plasma drug levels between 600 and 2900 ng/ml in each subject. Two subjects in the lowest dose group did not exhibit photosensitivity despite plasma drug levels as high as 4000 ng/ml.

Conclusions: These results indicate that a clinically effective dose of talaporfin sodium was well-tolerated and that cutaneous photosensitivity was mild and resolved relatively rapidly.



Plaats een reactie ...

Reageer op "Photosynthesizer bij PDT - talaporfin sodium - gemaakt van chlorophyl uit planten door FDA goedgekeurd voor gebruik bij PDT."

Gerelateerde artikelen

Gerelateerde artikelen

Fotosensitizers bij PDT - >> Fotosensitizers die gebruikt >> Fotosensitizers bij PDT - >>